6998 — Genor Biopharma Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.28bn
- HK$117.97m
- CNY206.23m
- 17
- 18
- 90
- 35
Annual cashflow statement for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3,036 | -866 | -732 | -677 | -35.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2,414 | 129 | -6.54 | 159 | 14.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -215 | 52.4 | 108 | 16.8 | -119 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -787 | -624 | -578 | -425 | -122 |
| Capital Expenditures | -98.3 | -71.4 | -13 | -1.03 | -1.57 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.049 | 17.1 | 0.015 | 7.02 | 9.58 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -98.2 | -54.3 | -12.9 | 5.99 | 8.01 |
| Financing Cash Flow Items | -111 | -2.36 | -2.86 | -0.888 | -0.112 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3,738 | 17.6 | -57.4 | -6.82 | -1.56 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,676 | -729 | -612 | -423 | -107 |